Computational Pathology to Guide Patient Selection for ADCs: Discovery of a Novel TROP2 NMR Biomarker for Predicting Clinical Outcomes
Time: 4:30 pm
day: Scientific Program Day One PM
Details:
- Computational pathology for revolutionizing the development and delivery of accurate biomarker, tailored to the drug’s mechanism of action
- Development of Quantitative Continuous Scoring (QCS) – an AI-based solution that allows interrogation of complex target and tumor biology
- Utilizing the novel computational pathology-based TROP2 NMR biomarker to predict clinical outcomes for Dato-DXd in NSCLC
